Table of Contents Author Guidelines Submit a Manuscript
Tuberculosis Research and Treatment
Volume 2011 (2011), Article ID 835410, 9 pages
http://dx.doi.org/10.1155/2011/835410
Review Article

Lactoferrin Augmentation of the BCG Vaccine Leads to Increased Pulmonary Integrity

1Department of Pathology, University of Texas Medical School at Houston, 6431 Fannin, Houston, TX 77030, USA
2Department of Integrative Biology and Pharmacology, University of Texas Medical School at Houston, 6431 Fannin, Houston, TX 77030, USA
3Department of Pathology and Laboratory Medicine, University of Texas Medical School at Houston, MSB 2.214 6431 Fannin, Houston, TX 77030, USA

Received 1 November 2010; Revised 19 January 2011; Accepted 1 March 2011

Academic Editor: Carlo Garzelli

Copyright © 2011 Shen-An Hwang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, WHO Report 2009. Global Tuberculosis Control. Epidemiology, Strategy, Financing, World Health Organization, Geneva, Switzerland, 2009.
  2. P. Andersen and T. M. Doherty, “The success and failure of BCG—implications for a novel tuberculosis vaccine,” Nature Reviews Microbiology, vol. 3, no. 8, pp. 656–662, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. A. C. Sterne, L. C. Rodrigues, and I. N. Guedes, “Does the efficacy of BCG decline with time since vaccination?” International Journal of Tuberculosis and Lung Disease, vol. 2, no. 3, pp. 200–207, 1998. View at Google Scholar · View at Scopus
  4. J. Liu, V. Tran, A. S. Leung, D. C. Alexander, and B. Zhu, “BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy,” Human Vaccines, vol. 5, no. 2, pp. 70–78, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. H. E. Kaufmann, “Future vaccination strategies against tuberculosis: thinking outside the Box,” Immunity, vol. 33, no. 4, pp. 567–577, 2010. View at Publisher · View at Google Scholar
  6. S. K. Parida and S. H. E. Kaufmann, “Novel tuberculosis vaccines on the horizon,” Current Opinion in Immunology, vol. 22, no. 3, pp. 374–384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. H. L. Robinson and R. R. Amara, “T cell vaccines for microbial infections,” Nature Medicine, vol. 11, no. 4, pp. S25–S32, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. R. G. Hewinson, “TB vaccines for the World,” Tuberculosis, vol. 85, no. 1-2, pp. 1–6, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. G. Hudgens and M. E. Halloran, “Causal vaccine effects on binary postinfection outcomes,” Journal of the American Statistical Association, vol. 101, no. 473, pp. 51–64, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Locht, C. Rouanet, J. M. Hougardy, and F. Mascart, “How a different look at latency can help to develop novel diagnostics and vaccines against tuberculosis,” Expert Opinion on Biological Therapy, vol. 7, no. 11, pp. 1665–1677, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. D. J. Padilla-Carlin, D. N. McMurray, and A. J. Hickey, “The guinea pig as a model of infectious diseases,” Comparative Medicine, vol. 58, no. 4, pp. 324–340, 2008. View at Google Scholar · View at Scopus
  12. D. O. Co, L. H. Hogan, S. I. Kim, and M. Sandor, “Mycobacterial granulomas: keys to a long-lasting host-pathogen relationship,” Clinical Immunology, vol. 113, no. 2, pp. 130–136, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. D. M. E. Bowdish, K. Sakamoto, M. J. Kim et al., “MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis,” PLoS Pathogens, vol. 5, no. 6, article e1000474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. T. V. Guidry, R. L. Hunter, and J. K. Actor, “CD3+ cells transfer the hypersensitive granulomatous response to mycobacterial glycolipid trehalose 6,6-dimycolate in mice,” Microbiology, vol. 152, no. 12, pp. 3765–3775, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. R. J. North and Y. J. Jung, “Immunity to tuberculosis,” Annual Review of Immunology, vol. 22, pp. 599–623, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Salgame, “Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection,” Current Opinion in Immunology, vol. 17, no. 4, pp. 374–380, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. K. J. Welsh, A. N. Abbott, S. A. Hwang et al., “A role for tumour necrosis factor-α, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6,6′-dimycolate induced granulomatous response,” Microbiology, vol. 154, no. 6, pp. 1813–1824, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Rao and O. Avni, “Molecular aspects of T-cell differentiation,” British Medical Bulletin, vol. 56, no. 4, pp. 969–984, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. S. A. Khader, G. K. Bell, J. E. Pearl et al., “IL-23 and IL-17 in the establishment of protective pulmonary CD4 T cell responses after vaccination and during Mycobacterium tuberculosis challenge,” Nature Immunology, vol. 8, no. 4, pp. 369–377, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. L. Kruzel, J. K. Actor, I. Boldogh, and M. Zimecki, “Lactoferrin in health and disease,” Postepy Higieny i Medycyny Doświadczalnej, vol. 61, pp. 261–267, 2007. View at Google Scholar · View at Scopus
  21. V. Deretic and R. A. Fratti, “Mycobacterium tuberculosis phagosome,” Molecular Microbiology, vol. 31, no. 6, pp. 1603–1609, 1999. View at Google Scholar · View at Scopus
  22. D. G. Russell, “What does “inhibition of phagosome-lysosome fusion” really mean?” Trends in Microbiology, vol. 6, no. 6, pp. 212–214, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. M. K. Katti, G. Dai, L. Y. Armitige et al., “The ?fbpA mutant derived from Mycobacterium tuberculosis H37Rv has an enhanced susceptibility to intracellular antimicrobial oxidative mechanisms, undergoes limited phagosome maturation and activates macrophages and dendritic cells,” Joural of Immunology, vol. 10, no. 6, pp. 1286–303, 2008. View at Google Scholar
  24. V. Deretic, S. Singh, S. Master et al., “Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism,” Cellular Microbiology, vol. 8, no. 5, pp. 719–727, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Jagannath, D. R. Lindsey, S. Dhandayuthapani, Y. Xu, R. L. Hunter Jr., and N. T. Eissa, “Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells,” Nature Medicine, vol. 15, no. 3, pp. 267–276, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. Cooper and S. A. Khader, “The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis,” Immunological Reviews, vol. 226, no. 1, pp. 191–204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. J. L. Flynn, “Immunology of tuberculosis and implications in vaccine development,” Tuberculosis, vol. 84, no. 1-2, pp. 93–101, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. G. A. W. Rook, K. Dheda, and A. Zumla, “Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?” Vaccine, vol. 23, no. 17-18, pp. 2115–2120, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. G. A. W. Rook, R. Hernandez-Pando, K. Dheda, and G. Teng Seah, “IL-4 in tuberculosis: implications for vaccine design,” Trends in Immunology, vol. 25, no. 9, pp. 483–488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. F. R. Vogel, “Improving vaccine performance with adjuvants,” Clinical Infectious Diseases, vol. 30, no. 3, pp. S266–S270, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. C. C. Dascher, K. Hiromatsu, X. Xiong et al., “Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis,” International Immunology, vol. 15, no. 8, pp. 915–925, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. J. K. Actor, S. A. Hwang, and M. L. Kruzel, “Lactoferrin as a natural immune modulator,” Current Pharmaceutical Design, vol. 15, no. 17, pp. 1956–1973, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. M. L. Kruzel and M. Zimecki, “Lactoferrin and immunologic dissonance: clinical implications,” Archivum Immunologiae et Therapiae Experimentalis, vol. 50, no. 6, pp. 399–410, 2002. View at Google Scholar · View at Scopus
  34. H. S. Birgens, “The interaction of lactoferrin with human monocytes,” Danish Medical Bulletin, vol. 38, no. 3, pp. 244–252, 1991. View at Google Scholar · View at Scopus
  35. M. L. Hammarstrom, L. Mincheva-Nilsson, and S. Hammarstrom, “Functional lactoferrin receptors on activated human lymphocytes,” Advances in Experimental Medicine and Biology, vol. 371, pp. 47–53, 1995. View at Google Scholar · View at Scopus
  36. S. Iyer, T. T. Yip, T. W. Hutchens, and B. Lonnerdal, “Lactoferrin-receptor interaction: effect of surface exposed histidine residues,” Advances in Experimental Medicine and Biology, vol. 357, pp. 245–252, 1994. View at Google Scholar · View at Scopus
  37. J. K. Actor, S. A. Hwang, M. Olsen, M. Zimecki, R. L. Hunter, and M. L. Kruzel, “Lactoferrin immunomodulation of DTH response in mice,” International Immunopharmacology, vol. 2, no. 4, pp. 475–486, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Legrand, E. Elass, M. Carpentier, and J. Mazurier, “Lactoferrin: a modulator of immune and inflammatory responses,” Cellular and Molecular Life Sciences, vol. 62, no. 22, pp. 2549–2559, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Zimecki, J. Mazurier, G. Spik, and J. A. Kapp, “Human lactoferrin induces phenotypic and functional changes in murine splenic B cells,” Immunology, vol. 86, no. 1, pp. 122–127, 1995. View at Google Scholar · View at Scopus
  40. M. K. Jenkins, A. Khoruts, E. Ingulli et al., “In vivo activation of antigen-specific CD4 T cells,” Annual Review of Immunology, vol. 19, pp. 23–45, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. A. H. Sharpe and G. J. Freeman, “The B7-CD28 superfamily,” Nature Reviews Immunology, vol. 2, no. 2, pp. 116–126, 2002. View at Google Scholar · View at Scopus
  42. S. L. Constant and K. Bottomly, “Induction of TH1 and TH2 CD4+ T cell responses: the alternative approaches,” Annual Review of Immunology, vol. 15, pp. 297–322, 1997. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Schmitt, P. Hoehn, C. Huels et al., “T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-γ and is inhibited by transforming growth factor-β,” European Journal of Immunology, vol. 24, no. 4, pp. 793–798, 1994. View at Google Scholar · View at Scopus
  44. S. A. Fulton, S. M. Reba, R. K. Pai et al., “Inhibition of major histocompatibility Complex II expression and antigen processing in murine alveolar macrophages by Mycobacterium bovis BCG and the 19-kilodalton Mycobacterial lipoprotein,” Infection and Immunity, vol. 72, no. 4, pp. 2101–2110, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Sendide, A. E. Deghmane, D. Pechkovsky, Y. Av-Gay, A. Talal, and Z. Hmama, “Mycobacterium bovis BCG attenuates surface expression of mature class II molecules through IL-10-dependent inhibition of cathepsin S,” Journal of Immunology, vol. 175, no. 8, pp. 5324–5332, 2005. View at Google Scholar · View at Scopus
  46. W. Wojciechowski, J. Desanctis, E. Skamene, and D. Radzioch, “Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guerin involves class II transactivator and depends on the Nramp1 gene,” Journal of Immunology, vol. 163, no. 5, pp. 2688–2696, 1999. View at Google Scholar · View at Scopus
  47. S. A. Hwang, M. L. Kruzel, and J. K. Actor, “Influence of bovine lactoferrin on expression of presentation molecules on BCG-infected bone marrow derived macrophages,” Biochimie, vol. 91, no. 1, pp. 76–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. K. M. Wilk, S. A. Hwang, and J. K. Actor, “Lactoferrin modulation of antigen-presenting-cell response to BCG infection,” Postepy Higieny i Medycyny Doświadczalnej, vol. 61, pp. 277–282, 2007. View at Google Scholar · View at Scopus
  49. S. A. Hwang and J. K. Actor, “Lactoferrin modulation of BCG-infected dendritic cell functions,” International Immunology, vol. 21, no. 10, pp. 1185–1197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Bhatia, M. Edidin, S. C. Almo, and S. G. Nathenson, “B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties,” Immunology Letters, vol. 104, no. 1-2, pp. 70–75, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Pentcheva-Hoang, J. G. Egen, K. Wojnoonski, and J. P. Allison, “B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse,” Immunity, vol. 21, no. 3, pp. 401–413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. C. S. Curran, K. P. Demick, and J. M. Mansfield, “Lactoferrin activates macrophages via TLR4-dependent and -independent signaling pathways,” Cellular Immunology, vol. 242, no. 1, pp. 23–30, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Spadaro, C. Caorsi, P. Ceruti et al., “Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells,” FASEB Journal, vol. 22, no. 8, pp. 2747–2757, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. J. K. Actor, S. A. Hwang, M. Olsen, M. Zimecki, R. L. Hunter, and M. L. Kruzel, “Lactoferrin immunomodulation of DTH response in mice,” International Immunopharmacology, vol. 2, no. 4, pp. 475–486, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. S. A. Hwang, M. L. Kruzel, and J. K. Actor, “Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis,” International Immunopharmacology, vol. 5, no. 3, pp. 591–599, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. B. K. Choi, J. K. Actor, S. Rios et al., “Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response,” Glycoconjugate Journal, vol. 25, no. 6, pp. 581–593, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. P. Derisbourg, J. M. Wieruszeski, J. Montreuil, and G. Spik, “Primary structure of glycans isolated from human leucocyte lactotransferrin. Absence of fucose residues questions the proposed mechanism of hyposideraemia,” Biochemical Journal, vol. 269, no. 3, pp. 821–825, 1990. View at Google Scholar · View at Scopus
  58. M. K. Gately, L. M. Renzetti, J. Magram et al., “The interleukin-12/interleukin-12-receptor systemml: role in normal and pathologic immune responses,” Annual Review of Immunology, vol. 16, pp. 495–521, 1998. View at Publisher · View at Google Scholar · View at Scopus
  59. E. E. Murphy, G. Terres, S. E. Macatonia et al., “B7 and interleukin 12 cooperate for proliferation and interferon γ production by mouse T helper clones that are unresponsive to B7 costimulation,” Journal of Experimental Medicine, vol. 180, no. 1, pp. 223–231, 1994. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Wakabayashi, N. Takakura, K. Yamauchi, and Y. Tamura, “Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin,” Clinical and Vaccine Immunology, vol. 13, no. 2, pp. 239–245, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. J. K. Kolls and A. Lindén, “Interleukin-17 family members and inflammation,” Immunity, vol. 21, no. 4, pp. 467–476, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. T. J. Scriba, B. Kalsdorf, D. A. Abrahams et al., “Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response,” Journal of Immunology, vol. 180, no. 3, pp. 1962–1970, 2008. View at Google Scholar · View at Scopus
  63. L. Mincheva-Nilsson, S. Hammarström, and M. L. Hammarström, “Activated human γδ T lymphocytes express functional lactoferrin receptors,” Scandinavian Journal of Immunology, vol. 46, no. 6, pp. 609–618, 1997. View at Google Scholar · View at Scopus
  64. I. Dhennin-Duthille, M. Masson, E. Damiens, C. Fillebeen, G. Spik, and J. Mazurier, “Lactoferrin upregulates the expression of CD4 antigen through the stimulation of the mitogen-activated protein kinase in the human lymphoblastic T Jurkat cell line,” Journal of Cellular Biochemistry, vol. 79, no. 4, pp. 583–593, 2000. View at Google Scholar · View at Scopus
  65. M. Zimecki, J. Mazurier, M. Machnicki, Z. Wieczorek, J. Montreuil, and G. Spik, “Immunostimulatory activity of lactotransferrin and maturation of CD4- and CD8- murine thymocytes,” Immunology Letters, vol. 30, no. 1, pp. 119–123, 1991. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Zimecki, R. Miedzybrodzki, J. Mazurier, and G. Spik, “Regulatory effects of lactoferrin and lipopolysaccharide on LFA-1 expression on human peripheral blood mononuclear cells,” Archivum Immunologiae et Therapiae Experimentalis, vol. 47, no. 4, pp. 257–264, 1999. View at Google Scholar · View at Scopus
  67. I. Frydecka, M. Zimecki, D. Bocko et al., “Lactoferrin-induced up-regulation of zeta (ζ) chain expression in peripheral blood T lymphocytes from cervical cancer patients,” Anticancer Research, vol. 22, no. 3, pp. 1897–1901, 2002. View at Google Scholar · View at Scopus
  68. M. Kociéba, M. Zimecki, M. Kruzel, and J. Actor, “The adjuvant activity of lactoferrin in the generation of DTH to ovalbumin can be inhibited by bovine serum albumin bearing α-D-mannopyranosyl residues,” Cellular and Molecular Biology Letters, vol. 7, no. 4, pp. 1131–1136, 2002. View at Google Scholar · View at Scopus
  69. M. Zimecki and M. L. Kruzel, “Systemic or local co-administration of lactoferrin with sensitizing dose of antigen enhances delayed type hypersensitivity in mice,” Immunology Letters, vol. 74, no. 3, pp. 183–188, 2000. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Zimecki, J. Mazurier, G. Spik, and J. A. Kapp, “Lactoferrin inhibits proliferative response cytokine production of TH1 but not TH2 cell lines,” Archivum Immunologiae et Therapiae Experimentalis, vol. 44, no. 1, pp. 51–56, 1996. View at Google Scholar · View at Scopus
  71. C. Guillén, I. B. McInnes, D. M. Vaughan et al., “Enhanced Th1 response to Staphylococcus aureus infection in human lactoferrin-transgenic mice,” Journal of Immunology, vol. 168, no. 8, pp. 3950–3957, 2002. View at Google Scholar · View at Scopus
  72. N. Takakura, H. Wakabayashi, K. Yamauchi, and M. Takase, “Influences of orally administered lactoferrin on IFN-γ and IL-10 production by intestinal intraepithelial lymphocytes and mesenteric lymph-node cells,” Biochemistry and Cell Biology, vol. 84, no. 3, pp. 363–368, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. W. P. Wang, M. Iigo, J. Sato, K. Sekine, I. Adachi, and H. Tsuda, “Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin,” Japanese Journal of Cancer Research, vol. 91, no. 10, pp. 1022–1027, 2000. View at Google Scholar · View at Scopus
  74. S. A. Hwang, K. M. Wilk, Y. A. Bangale, M. L. Kruzel, and J. K. Actor, “Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes,” Medical Microbiology and Immunology, vol. 196, no. 3, pp. 171–180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. K. Ishii, N. Takamura, M. Shinohara et al., “Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months,” Hepatology Research, vol. 25, no. 3, pp. 226–233, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Fischer, H. Debbabi, M. Dubarry, P. Boyaka, and D. Tomé, “Regulation of physiological and pathological Th1 and Th2 responses by lactoferrin,” Biochemistry and Cell Biology, vol. 84, no. 3, pp. 303–311, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. H. Debbabi, M. Dubarry, M. Rautureau, and D. Tomé, “Bovine lactoferrin induces both mucosal and systemic immune response in mice,” Journal of Dairy Research, vol. 65, no. 2, pp. 283–293, 1998. View at Publisher · View at Google Scholar · View at Scopus
  78. R. M. Sfeir, M. Dubarry, P. N. Boyaka, M. Rautureau, and D. Tomé, “The mode of oral bovine lactoferrin administration influences mucosal and systemic immune responses in mice,” Journal of Nutrition, vol. 134, no. 2, pp. 403–409, 2004. View at Google Scholar · View at Scopus
  79. J. Artym, M. Zimecki, and M. L. Kruzel, “Effect of lactoferrin on the methotrexate-induced suppression of the cellular and humoral immune response in mice,” Anticancer Research, vol. 24, no. 6, pp. 3831–3836, 2004. View at Google Scholar · View at Scopus
  80. J. Artym, M. Zimecki, M. Paprocka, and M. L. Kruzel, “Orally administered lactoferrin restores humoral immune response in immunocompromised mice,” Immunology Letters, vol. 89, no. 1, pp. 9–15, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. S. A. Hwang, K. Wilk, M. L. Kruzel, and J. K. Actor, “A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice,” Vaccine, vol. 27, no. 23, pp. 3026–3034, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. M. L. Kruzel, Y. Harari, C. Y. Chen, and G. A. Castro, “Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice,” Inflammation, vol. 24, no. 1, pp. 33–44, 2000. View at Publisher · View at Google Scholar · View at Scopus
  83. S. A. Hwang, K. M. Wilk, M. Budnicka et al., “Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis,” Vaccine, vol. 25, no. 37-38, pp. 6730–6743, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. S.-A. Hwang, R. Arora, M. L. Kruzel, and J. K. Actor, “Lactoferrin enhances efficacy of the BCG vaccine: comparison between two inbred mice strains (C57BL/6 and BALB/c),” Tuberculosis, vol. 89, supplement 1, pp. S49–S54, 2009. View at Publisher · View at Google Scholar
  85. J. J. Ellner, “Immunoregulation in TB: observations and implications,” Clinical and Translational Science, vol. 3, no. 1, pp. 23–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Actor, R. Hunter, and C. Jagannath, “Immunopathology of tuberculosis,” in Molecular Pathology of Lung Diseases, D. Zander, H. Popper, J. Jagirdar, A. Haque, P. Cagle, and R. Barrios, Eds., Springer, Florissant, Miss, USA, 2008. View at Google Scholar
  87. R. Hernandez-Pando, H. Orozco, and D. Aguilar, “Factors that deregulate the protective immune response in tuberculosis,” Archivum Immunologiae et Therapiae Experimentalis, vol. 57, no. 5, pp. 355–367, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. R. L. Hunter, L. Armitige, C. Jagannath, and J. K. Actor, “TB Research at UT-Houston—a review of cord factor: new approaches to drugs, vaccines and the pathogenesis of tuberculosis,” Tuberculosis, vol. 89, no. 1, pp. S18–S25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. D. G. Russell, P. J. Cardona, M. J. Kim, S. Allain, and F. Altare, “Foamy macrophages and the progression of the human tuberculosis granuloma,” Nature Immunology, vol. 10, no. 9, pp. 943–948, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. I. M. Orme, D. N. McMurray, and J. T. Belisle, “Tuberculosis vaccine development: recent progress,” Trends in Microbiology, vol. 9, no. 3, pp. 115–118, 2001. View at Publisher · View at Google Scholar · View at Scopus
  91. P. E. M. Fine, “Herd immunity: history, theory, practice,” Epidemiologic Reviews, vol. 15, no. 2, pp. 265–302, 1993. View at Google Scholar · View at Scopus
  92. S. L. Baldwin, C. D'Souza, A. D. Roberts et al., “Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis,” Infection and Immunity, vol. 66, no. 6, pp. 2951–2959, 1998. View at Google Scholar · View at Scopus
  93. D. N. McMurray, “A coordinated strategy for evaluating new vaccines for human and animal tuberculosis,” Tuberculosis, vol. 81, no. 1-2, pp. 141–146, 2001. View at Publisher · View at Google Scholar · View at Scopus